MENS

Jyong Biotech Ltd. Ordinary Shares NASDAQ Listed Jun 17, 2025

Healthcare ·Biotechnology ·TW · jyongbio.com/

$2.02

-1.94% vs $2.06

Mkt Cap $153.6M

52w Low $1.43 0.9% of range 52w High $67.00

50d MA $2.07 200d MA $7.79

P/E (TTM) —

EV/EBITDA —

P/B —

Debt/Equity -0.5x

ROE —

P/FCF -42.4x

RSI (14) 21.10

ATR (14) $0.19

Beta 8.47

50d MA $2.07

200d MA $7.79

Avg Volume 52.9K

Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stages

SIC Code

2834

CIK (SEC)

1954488

Phone

886 2 2732 5205

23F‑3, No. 95, Section 1, Xintai 5th Road · New Taipei City 221 · TW

Institutional (13F) — Top 11 All ↗

#	Manager	Shares	Value	Chg	Period
1	Jane Street Group, Llc	69,560	$275K	New	Dec 2025
2	Morgan Stanley	56,226	$222K	Added	Dec 2025
3	Ubs Group Ag	37,363	$80K	Reduced	Mar 2026
4	China Universal Asset Management Co., Ltd.	12,389	$49K	New	Dec 2025
5	Millennium Management	14,590	$31K	Reduced	Mar 2026
6	Vanguard Personalized Indexing Management, Llc	13,927	$30K	New	Mar 2026
7	Hrt Financial Lp	11,767	$25K	New	Mar 2026
8	Barclays Plc	5,189	$11K	Added	Mar 2026
9	Jpmorgan Chase & Co	5,679	$11K	Reduced	Mar 2026
10	Bnp Paribas Financial Markets	1,881	$4K	Added	Mar 2026
11	Royal Bank Of Canada	266	$1K	New	Mar 2026

Mutual Funds / ETFs (N-PORT) — Top 1 All ↗

#	Fund	Shares	Value	Period
1	Invesco Nasdaq Biotechnology ETF	4,238	$9K	Feb 2026

Data updated apr 26, 2026 11:51am · Source: financialmodelingprep.com